<DOC>
	<DOCNO>NCT00735644</DOCNO>
	<brief_summary>This study ass safety immunogenicity three consecutive lot JE-CV toddler age 12-18 month . Primary objective : To demonstrate bio-equivalence three lot JE-CV vaccine manufacture sanofi pasteur . Secondary objective : To describe safety vaccination subject</brief_summary>
	<brief_title>Study ChimeriVax™-Japanese Encephalitis Vaccine Toddlers Thailand Philippines</brief_title>
	<detailed_description>This Phase III trial toddler Thailand Philippines .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Encephalitis , Japanese</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Aged 12 18 month day inclusion . In good general health , without significant medical history . Provision informed consent form sign least one parent legally acceptable representative , least one independent witness require local regulation . Subject parent/legally acceptable representative able attend schedule visit comply trial procedure . Completion vaccination accord national immunization schedule . Exclusion Criteria : Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede trial vaccination . Planned participation another clinical trial present trial period . Known suspect congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy . Known systemic hypersensitivity vaccine component history lifethreatening reaction vaccine contain substance . Chronic illness stage could interfere trial conduct completion , opinion Investigator . Receipt blood bloodderived product past 3 month , might interfere assessment immune response . Administration antiviral within 2 month precede V01 . History central nervous system disorder disease , include seizure . Personal family history thymic pathology ( thymoma ) , thymectomy , myasthenia . Receipt vaccine 4 week precede first trial vaccination . Planned receipt vaccine 4 week follow trial vaccination . Personal human immunodeficiency virus seropositivity blood sample take screening . Receipt JE vaccine hepatitis A vaccine . Previous vaccination flavivirus disease . History flavivirus infection ( confirm either clinically , serologically microbiologically ) Thrombocytopenia , bleed disorder anticoagulant 3 week precede inclusion contraindicate intramuscular vaccination . Febrile illness ( temperature ≥38°C ) moderate severe acute illness/infection day vaccination , accord Investigator judgment .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Japanese encephalitis , Hepatitis A , Inactivated Mouse-Brain</keyword>
</DOC>